Provide comprehensive kidney dialysis treatment and associated services. Operate a vast network of outpatient dialysis clinics globally. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
The market pays 10.6× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 95% of them.
Analysts' average target sits 5% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
The price looks reasonable next to what the company earns.
This grade is a blend: the profit side is strong, the sales tempo slow.
The price is looking for direction — no strong breakout, no collapse.
Financial Strength: The cash-and-debt balance is thin; the buffer for hard times is slim.
The stock trades 38% below its peak. The market has trimmed its expectations for the company.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
It pays out $0.86 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 3% a year on average — the report card’s higher growth grade leans on profit power instead.
The balance sheet offers little cushion against a rough stretch. Report-card grade: 38/100.
Since the drop from its peak, buyer appetite hasn’t come back.
On our five-subject report card, FMS sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: FMS is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.